Followers | 110 |
Posts | 20257 |
Boards Moderated | 0 |
Alias Born | 05/08/2008 |
Wednesday, December 13, 2017 4:13:58 PM
“Effective June 15, 2017, the Company completed the acquisition of 10800034 B.C. Ltd. (“0034 BC), to which the Company acquired a 100% interest in 0034 BC, a private Canadian company that has two wholly-owned subsidiaries, FN Pharmaceuticals, and FN Management. Additionally, 0034 BC held at Letter of Intent to purchase 91% of AMA and a separate Letter of Intent to purchase 91% of Infused.
In connection with the acquisition of 0034 BC, 0034 BC holds an 8% equity interest in two LLC companies, BiVi LLC, and Bellissima LLC, that respectively own two liquor brands (Note 6). The Company considered various valuation techniques in determining the fair value of the investments in BiVi LLC and Bellissima LLC. The Company considered (i) the market approach; (ii) the cost approach; and (iii) the income approach and determined that the income approach was the most appropriate method as there is insufficient information available to apply the alternative technique. The income approach converts future amounts to a single current discounted amount.
The fair value measurement using the income approach reflects current market expectations about those future amounts. On June 15, 2017, the fair value of the investments in BiVi LLC and Bellissima LLC was determined to be $nil due to one or more of the following reasons for each respective investment:
? Cash flows generated by the Company from these investments is $nil to date;
? Distribution of the brand is minimal at this time;
? Sales levels are uncertain and below expectations; and
? Business and marketing plans are stalled with minimal budgeted future plans.
"A man sees in the world what he carries in his heart" ** Johann Wolfgang Von Goethe
"Never does a man portray his own character more vividly, than in his manner of portraying another" -- Richter
Recent ICNB News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 06/29/2023 09:21:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/29/2023 12:51:54 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM